Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96

Antiviral Therapy

Volumn 14, Issue 6, 2009, Pages 859-864

  Arastéh, Keikawus ^a   Yeni, Patrick ^b   Pozniak, Anton ^c   Grinsztejn, Beatriz ^d   Jayaweera, Dushyantha ^e   Roberts, Afsoon ^f   Hoy, Jennifer ^g   De Meyer, Sandra ^h   Vangeneugden, Tony ^h   Tomaka, Frank ⁱ  

^a Vivantes Auguste Viktoria Klinikum   (Germany)

^b BICHAT HOSPITAL   (France)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d Funda??o Oswaldo Cruz   (Brazil)

^e UNIVERSITY OF MIAMI   (United States)

^f GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^g ALFRED HOSPITAL   (Australia)

^h TIBOTEC BVBA   (Belgium)

ⁱ Tibotec Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; VIRUS RNA;

ACUTE KIDNEY FAILURE; ARTHRALGIA; ARTICLE; BRONCHITIS; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; IMMUNE RESPONSE; INFLUENZA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPHIL; PARTIAL THROMBOPLASTIN TIME; PNEUMONIA; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; THROMBOCYTE COUNT; VIRUS MUTATION; VOMITING;

ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV-1; HUMANS; RITONAVIR; SULFONAMIDES;

EID: 72049085508     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1301     Document Type: Article

References (14)

1. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21:395-402. (Pubitemid 46263249)
2. Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007; 21:F11-F18. (Pubitemid 46568621)
3. Molina J-M, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007; 46:24-31. (Pubitemid 47514614)
4. Saag M, Falcon R, Lefebvre E. Efficacy and safety results of darunavir/ritonavir in treatment-experienced patients: POWER 3. 44th Annual Meeting of the Infectious Diseases Society of America. 12-15 October 2006, Toronto, ON, Canada. Poster 9570.
5. Clotet B, Bellos N, Molina J-M, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178. (Pubitemid 46541620)
6. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370:49-58. (Pubitemid 47023100)
7. Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22:1389-1397.
8. D'Aquila RT, Schapiro JM, Brun-Vézinet F, et al. Drug resistance mutations in HIV-1. Top HIV Med 2003; 11:92-96.
9. Johnson VA, Brun-Vézenit B, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med 2004; 12:119-124.
10. Haubrich R, Cahn P, Grinsztejn B, et al. DUET-1: week 48 results of a phase III randomised double-blind trial to evaluate the efficacy and safety of TMC125 versus placebo in 612 treatment-experienced HIV-1 infected patients. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 790.
11. Johnson M, Campbell T, Clotet B, et al. DUET-2: week 48 results of a phase III randomised double-blind trial to evaluate the efficacy and safety of TMC125 versus placebo in 591 treatment-experienced HIV-1 infected patients. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 791.
12. Cooper DA, Gatell J, Rocktroh J, et al. 48-Week results from BENCHMRK-1, a phase III study of raltegravir in patients failing ART with triple-class resistant HIV-1. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008; Boston, MA, USA. Abstract 788.
13. Steigbigel R, Kumar P, Eron J, et al. 48-week results from BENCHMRK-2, a phase III study of raltegravir in patients failing ART with triple-class resistant HIV. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Poster 789.
14. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents. US Department of Health and Human Services. November 3, 2008 (Updated 3 November 2008. Accessed 9 April 2009.) Available from www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf